Tuesday, December 06, 2022 12:06:55 PM
Great feed back. The 500 people in the trial data set not yet examined, is not based on today's SOC Standard of Care basis. It was the SOC during the trials...
300+ people are still dying daily from Covid19 in the US, so the SOC still sucks LOL. And 300,000 new cases per day getting it. Repeat infections are leading to more health issues and deaths
I hope MF is looking into tracking down the long haul covid19 status of the 710+ test cases....
to see if that is worth adding to the data....
300+ people are still dying daily from Covid19 in the US, so the SOC still sucks LOL. And 300,000 new cases per day getting it. Repeat infections are leading to more health issues and deaths
I hope MF is looking into tracking down the long haul covid19 status of the 710+ test cases....
to see if that is worth adding to the data....
Bullish
Recent RVVTF News
- Revive Therapeutics Announces Strategic Expansion of Bucillamine Program Across Infectious Diseases, Defence and Biothreat Medical Countermeasures • ACCESS Newswire • 05/20/2026 11:45:00 AM
- Revive Therapeutics Strengthens Bucillamine IP Portfolio with North American Patent Filings for Nerve Agent Exposure and Granted Canadian Patent for Infectious Diseases • ACCESS Newswire • 03/11/2026 11:30:00 AM
- Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study • GlobeNewswire Inc. • 12/15/2025 12:30:00 PM
- Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study • GlobeNewswire Inc. • 11/21/2025 05:07:49 PM
- Revive Therapeutics Announces Closing of Second Tranche of Private Placement • GlobeNewswire Inc. • 09/19/2025 09:00:28 PM
